<p>We measured CY and CY metabolites in blood plasma samples from patients receiving high-dose CY and here present the concentration–time profiles obtained from all three patients for (A) CY, (B) HCY, and (C) CEPM. Underlying diseases were acute mixed lineage leukemia (male, 8 y.o.; open square) and granulocytic sarcoma (male, 17 y.o.; open circle), and acute myeloid leukemia (male, 1 y.o.; open triangle).</p
Despite the remarkable clinical response rates to imatinib in the treatment of bcr-abl leukemic pati...
Plasma levels of cyclic nucleotides were measured in 71 patients with acute leukemia [50 patients wi...
This article describes the enantioseleclive analysis of cyclophosphamide (CPA) in human plasma using...
Due to variation in drug distribution, metabolism and elimination processes between patients, system...
Cyclophosphamide-based regimens are front-line treatment for numerous pediatric malignancies; howeve...
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.Backgro...
AbstractIntroductionVariation in cyclophosphamide pharmacokinetics and metabolism has been highlight...
Cyclophosphamide (CPA) is widely used anti-cancer drug that has to be catalyzed by the cytochrome P4...
Pharmacokinetic and pharmacodynamic studies are an essential in order to achieve better treatment ef...
Cyclophosphamide (CP) is an antineoplastic drug used to treat a wide variety of cancers and immune d...
Prolonged, frequently administered low-dose metronomic chemotherapy (LDM) is being explored (pre)cli...
Objective: To quantify 4-hydroxycyclophosphamide in cancer patients' plasma for therapeutic drug mon...
OBJECTIVES: Cyclophosphamide (CP) is an alkylating agent classified as a human carcinogen. Health ca...
AIMS: To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cycloph...
A rapid and selective method for simultaneous determination of cyclophosphamide and its metabolite c...
Despite the remarkable clinical response rates to imatinib in the treatment of bcr-abl leukemic pati...
Plasma levels of cyclic nucleotides were measured in 71 patients with acute leukemia [50 patients wi...
This article describes the enantioseleclive analysis of cyclophosphamide (CPA) in human plasma using...
Due to variation in drug distribution, metabolism and elimination processes between patients, system...
Cyclophosphamide-based regimens are front-line treatment for numerous pediatric malignancies; howeve...
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.Backgro...
AbstractIntroductionVariation in cyclophosphamide pharmacokinetics and metabolism has been highlight...
Cyclophosphamide (CPA) is widely used anti-cancer drug that has to be catalyzed by the cytochrome P4...
Pharmacokinetic and pharmacodynamic studies are an essential in order to achieve better treatment ef...
Cyclophosphamide (CP) is an antineoplastic drug used to treat a wide variety of cancers and immune d...
Prolonged, frequently administered low-dose metronomic chemotherapy (LDM) is being explored (pre)cli...
Objective: To quantify 4-hydroxycyclophosphamide in cancer patients' plasma for therapeutic drug mon...
OBJECTIVES: Cyclophosphamide (CP) is an alkylating agent classified as a human carcinogen. Health ca...
AIMS: To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cycloph...
A rapid and selective method for simultaneous determination of cyclophosphamide and its metabolite c...
Despite the remarkable clinical response rates to imatinib in the treatment of bcr-abl leukemic pati...
Plasma levels of cyclic nucleotides were measured in 71 patients with acute leukemia [50 patients wi...
This article describes the enantioseleclive analysis of cyclophosphamide (CPA) in human plasma using...